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Edited by Varda RotterAbstract The goal of the current study, conducted in freshly
isolated thymocytes was (1) to investigate the possibility that
the activation of poly(ADP-ribose) polymerase-1 (PARP-1) in
an intact cell can be regulated by protein kinase C (PKC) med-
iated phosphorylation and (2) to examine the consequence of this
regulatory mechanism in the context of cell death induced by the
genotoxic agent. In cells stimulated by the PKC activating phor-
bol esters, DNA breakage was unaﬀected, PARP-1 was phos-
phorylated, 1-methyl-3-nitro-1-nitrosoguanidine-induced PARP
activation and cell necrosis were suppressed, with all these eﬀects
attenuated by the PKC inhibitors GF109203X or Go¨6976. Inhi-
bition of cellular PARP activity by PKC-mediated phosphoryla-
tion may provide a plausible mechanism for the previously
observed cytoprotective eﬀects of PKC activators.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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nitrosoguanidine1. Introduction
The nuclear enzyme poly(ADP-ribose) polymerase 1
(PARP-1), a highly conserved constitutively-expressed 116
kDa protein is the most abundant isoform of the PARP en-
zyme family with roles in regulating multiple cellular functions
in health and disease (overviewed in [1,2]). Poly(ADP-ribo-
syl)ation has been implicated in the regulation of multiple
physiological cellular functions such as DNA repair, gene tran-Abbreviations: DMSO, dimethylsulfoxide; DTT, dithiothreitol;
MNNG, 1-methyl-3-nitro-1-nitrosoguanidine; MTT, 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide; PARP, poly(ADP-ri-
bose) polymerase; PI, propidium iodide; PMA, phorbol 12-myristate
13-acetate; PKC, protein kinase C
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doi:10.1016/j.febslet.2008.04.023scription, cell cycle progression, cell death, chromatin function
and genomic stability [3]. Because PARP-1 becomes activated
in response to DNA breaks, the nature of the various endoge-
nous species capable of inducing DNA strand breaks (and
thereby activating PARP-1) in various disease conditions be-
came of crucial interest. In addition to hydroxyl radical, perox-
ynitrite (a reactive nitrogen species formed from the diﬀusion-
limited reaction of nitric oxide and superoxide anion) has been
identiﬁed as a pathophysiologically relevant trigger of PARP
activation [2].
From a pathophysiological standpoint, PARP activation
can contribute to the development of disease via two main
mechanisms: (a) by driving the cell into an energetic deﬁcit
and a state of dysfunction and (b) by catalyzing the activation
of pro-inﬂammatory pathways. As far as the former pathway:
PARP-1 functions as a DNA damage sensor and signaling
molecule binding to both single- and double-stranded DNA
breaks. Upon binding to damaged DNA, PARP-1 forms
homodimers and catalyzes the cleavage of NAD+ into nicotin-
amide and ADP-ribose to form long branches of (ADP-
ribose)n polymers on target proteins including histones and
PARP-1 itself. This process results in cellular energetic deple-
tion, mitochondrial dysfunction and ultimately necrosis [1,2].
As far as the latter pathway: numerous transcription factors,
DNA replication factors and signaling molecules have also
been shown to become poly(ADP-ribosyl)ated by PARP-1,
but a PARP-mediated activation of the pluripotent transcrip-
tion factor nuclear factor kappa B (NF-jB) appears to be of
crucial importance [1,4]. Multiple lines of studies demonstrate
that neutralization of peroxynitrite and/or pharmacological
inhibition or genetic inactivation of PARP-1 is therapeutically
eﬀective in a wide range of cardiovascular, inﬂammatory, vas-
cular and neurodegenerative diseases, both by protecting
against cell death as well as by down-regulating multiple
inﬂammatory pathways [1].
The activity of PARP-1 at the cellular level is primarily
regulated by DNA single strand breaks. These breaks are rec-
ognized by zinc-ﬁngers of PARP-1, and induce a conforma-
tional change in the enzyme, which, in turn, results in an
increased catalysis of NAD+ to ADP-ribose units and nicotin-
amide, as the byproduct of the reaction [2]. However, a num-
ber of studies have also suggested alternative (i.e. non-DNA
break dependent) intracellular regulatory mechanisms forblished by Elsevier B.V. All rights reserved.
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lar functional alterations. Some of these regulators (over-
viewed in [5]) include calcium, female sex hormones,
xanthines and other factors. There are two published studies
[6,7] demonstrating the ability of protein kinase C (PKC) to
phosphorylate PARP-1 in in vitro systems. The current study,
conducted in freshly isolated thymocytes has investigated the
possibility that the activation of PARP in an intact cell can
be regulated by phosphorylation via PKC and examined the
consequence of this regulatory mechanism in the context of cell
death induced by nitrosative stress.2. Materials and methods
2.1. Materials
Propidium iodide (PI) was purchased from Molecular Probes
(Eugene, OR, USA). All other chemicals, including 1-methyl-3-nitro-
1-nitrosoguanidine (MNNG) were from Sigma–Aldrich (St. Louis,
MO, USA). The water soluble PARP inhibitor, PJ-34 [8] was produced
by Inotek Pharmaceuticals (Beverly, MA, USA).
2.2. Cytotoxicity assay
Thymocytes were prepared according to Bai et al.[9] and Virag et al.
[10] MNNG-induced cytotoxicity was measured by propidium iodide
(PI) uptake as described previously [9]. Cytotoxicity has also been
determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay, as described [11] with the exception that treat-
ments were carried out in Eppendorf tubes and cells were spun down
before removal of the medium and addition of dimethylsulfoxide
(DMSO).
2.3. PARP activity assay
PARP activity of cells was determined with the traditional PARP
activity assay based on the incorporation of isotope from 3H-NAD+
into TCA (trichloroacetic acid)-precipitable proteins as described [10].
2.4. Caspase activity assay
Caspase-3 like activity was detected as described previously [12].
2.5. Single cell gel electrophoresis (comet-assay)
Single-stranded DNA strand breaks were assayed by single cell gel
electrophoresis (comet assay) according to Singh et al. [13] with mod-
iﬁcations as described in [12].
2.6. Immunoprecipitation
PARP-1 phosphorylation was detected by immunoprecipitation.
Cells were lysed with sample buﬀer (150 mM NaCl, 1% Triton-X
100, 50 mMTris–HCl (pH 8.0), 1 mM EDTA, protease inhibitor cock-
tail (100·), 1 mM NaF, 1 mM Na2VO3), sonicated for 20 s. Samples
were precleared with 20 ll 50% sepharose-protein-A slurry for 1 h.
Samples were incubated for 1.5 h with anti-PARP antibody (4 lg pro-
tein/500 ll sample). Fifty microliters of 50% sepharose-protein-A slur-
ry were added and incubated for 1 h. Sepharose-protein-A microbeads
were washed three times with sample buﬀer. Microbeads were mixed
with SDS sample buﬀer then subjected toSDS–polyacrylamide gel elec-
trophoresis in 8% gels and transferred onto nitrocellulose membranes
in 25 mM Tris/HCl, pH 8.3, containing 192 mM glycine, 0.02% (w/v)
SDS and 20% (v/v) methanol at 250 mA for 90 min.
2.7. Western blotting and immunoﬂuorescence
For Western blotting, cells were lysed with RIPA buﬀer, sonicated
for 20 s, and mixed with SDS sample buﬀer than subjected to SDS–
polyacrylamide gel electrophoresis in 8% gels and transferred onto
nitrocellulose membranes in 25 mM Tris/HCl, pH 8.3, containing
192 mM glycine, 0.02% (w/v) SDS and 20% (v/v) methanol at
250 mA for 90 min. immunostaining was performed using polyclonal
anti-poly(ADP-ribose), anti-PARP-1 antibody, isoform speciﬁc anti-
PKC and anti-phosphoserine antibodies according to standard proce-
dures as described in [12,14]. The same anti-PKC antibodies have beenused for immunoﬂuorescence stainings with FITC-conjugated second-
ary antibody according to standard procedures. Nuclei were counter-
stained with DAPI. Images were acquired with a Zeiss LSM 510
META confocal laser scanning microscope and z-stacked green and
blue images were overlaid. Representative images are shown.
2.8. In vitro phosphorylation
Puriﬁed PARP-1 enzyme was phosphorylated by puriﬁed cPKC
mixture (alpha, beta, gamma isoforms) in HEPES assay buﬀer
(200 mM HEPES pH 7.5; 100 mM MgCl2, 10 mM dithiothreitol
(DTT)). PKC was diluted in PKC storage buﬀer (20 mM HEPES
pH7,5, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 25% glycerine,
0.02 % NaN3, 0.05% Triton X-100) to a ﬁnal concentration of
0.1 lg/ml and was activated by the addition of 0.65 mM CaCl2 and
phosphatidyl serine–diolein micellas. ATP mixture (5 ll) containing
0.988 mM ATP and 20-fold diluted 32P-ATP were added to the sam-
ples. Samples were incubated for 20, 50 and 90min. Controls were pre-
pared with the omission of PKC. Samples were mixed with SDS
sample buﬀer and subjected toSDS–polyacrylamide gel electrophoresis
in 8% gels. Gels were dried. 32P signals were detected by autoradiogra-
phy.
2.9. Statistical analysis
All experiments were preformed three times on diﬀerent days. Stu-
dents t-test was applied for statistical analysis and for the determina-
tion of signiﬁcance with P < 0.05 considered as signiﬁcant. For the
statistical analysis of the comet assay experiments, Mann and Whit-
neys U-test was applied.3. Results
First, we have tested whether modulation of PKC activity
aﬀects PARP activation in thymocytes. Cells were treated with
the prototypical DNA-damaging agent MNNG, which has the
well-documented eﬀect of inducing DNA single strand break-
age, and subsequent PARP activation [12]. As expected,
MNNG induced a marked degree of PARP activation
(Fig. 1), which was suppressed by the PARP inhibitor PJ34
(Fig. 1). When cells were pretreated for 30 min with the PKC
activator phorbol ester phorbol 12-myristate 13-acetate
(PMA), a signiﬁcant suppression of MNNG-induced PARP
activation was observed (Fig. 1). The PARP-inhibitory eﬀect
of PMA was largely reversed by the compound bisindolylmale-
imide (GF109203X), a broad spectrum PKC inhibitor and was
partially attenuated by Go¨6976 an inhibitor of conventional
(calcium-dependent) PKC isoforms (Fig. 1).
In order to investigate the consequences of PKC inhibition
in the context of MNNG-induced cell death, we have mea-
sured the MNNG-induced changes in overall cell viability,
necrotic cell death (propidium iodide uptake) and caspase acti-
vation, a measure of apoptotic cell death. As expected,
MNNG signiﬁcantly reduced cell viability and increased ne-
crotic cell death as compared to control (Fig. 2). The cell death
was dependent on PARP activation in this model, as evidenced
by the inhibitory eﬀect of the PARP inhibitor PJ34 (Fig. 2).
Consistent with its PARP-inhibitory eﬀect, PMA pretreatment
attenuated MNNG-induced thymocyte cell necrosis (Fig. 2A
and B). As shown in previous experiments using PARP-depen-
dent death of murine thymocytes, inhibition of cell necrosis by
PARP inhibitors maintains cellular NAD+ and ATP levels and
increases cellular energy charge [10,15]. These eﬀects are asso-
ciated with an increase in the population of normal cells (not
necrotic or apoptotic), with a decrease in the population of ne-
crotic cells, as well as an increase in the population of apopto-
tic cells [10,15]. The current results, showing an increase in
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Fig. 1. PKC activation suppresses MNNG-induced PARP activation.
Cells were treated with 20 lM MNNG for 10 min. Some samples were
pretreated for 30 min with 100 nM PMA or with the PARP inhibitor
PJ34 (3 lM). In some samples, PMA treatment was preceded with a
30 min treatment with the PKC inhibitors GF109203X and Go¨6976.
PARP activity of permeabilized cells was determined in 3H-NAD
incorporation assay (A) and poly(ADP-ribose) of cell lysates was
determined by Western blotting (B). Means ± S.E.M. of three
independent experiments are presented. MNNG signiﬁcantly
(**P< 0.01) increased PARP activity as compared to control. PMA
signiﬁcantly (##P < 0.01) reduced MNNG-induced PARP activation.
The eﬀect of PMA was prevented by GF109203X (P < 0.01) and less
eﬀectively by Go¨6976 (P < 0.01).
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PMA (Fig. 2C) are consistent with a similar pattern of shift
in cellular death pathways. The eﬀect of PMA in attenuating
cell necrosis was prevented by pretreatment of the cells with
the PKC inhibitors GF109203X and by Go¨6976 (Fig. 2A
and B).
Next, the PKC expression pattern of the thymocytes was
determined by Western blotting (Fig. 2D). We have found evi-
dence for all PKC isoforms in the cells (Fig. 2D). (The full
images of Western blots are shown in Figure S1.)
Because PKC can aﬀect a wide variety of cell functions, we
have designed a control experiment to test whether the degree
of DNA strand breakage induced by MNNG can be aﬀected
by the PKC activator and inhibitor compounds used. The
PKC activator PMA (in the absence or presence of the PKC
inhibitors GF109203X and Go¨6976) had no eﬀect on the de-gree of DNA strand breakage induced by MNNG (Fig. 3).
The positive control glutathione (10 mM) abolished MNNG-
induced DNA breakage. This ﬁnding is consistent with the
view that it is not the initial trigger of PARP activation (i.e.
DNA strand breakage), but some other downstream cellular
pathway (such as PARP activity itself) is aﬀected by the
PKC modulators used in the current study.
Finally, we have set out to determine whether the eﬀects of
PKC activator and the PKC inhibitors are associated with a
direct phosphorylation of PARP1 in PMA-stimulated thymo-
cytes. Phosphorylation of PARP1 was detected by two-way
immunoprecipitation and Western blotting. As shown in Fig.
4A, when PARP1 was immunoprecipitated and phosphoryla-
tion was detected by P-Ser antibody, PMA induced a signiﬁ-
cant phosphorylation of PARP, which was attenuated by
both PKC inhibitors used. Similar results were observed in
other series of experiments, when immunoprecipitation was
carried out with P-Ser antibody and PARP1 was detected in
Western blots (not shown). Puriﬁed PARP1 was also shown
to be phosphorylated in vitro by PKC, as detected by autora-
diography (Fig. 4C).4. Discussion
The current study was designed to examine whether PARP-1
may be a substrate of PKC in an intact cell system, and if so,
whether this interaction can have functional consequences for
the regulation of DNA damage-induced necrosis. PARP-1 has
been reported to be substrate for kinases [16,17] implicating
the possibility of the regulation of PARP-1 activity by phos-
phorylation. PARP-1 is in close association with the DNA-
dependent protein kinase (DNA-PK), which has been shown
to phosphorylate PARP-1 [17]. Furthermore, puriﬁed PARP-
1 has been reported to serve as a substrate for PKC, with a
consequent inhibition of PARPs DNA-binding capacity and
catalytic activity [6,7]. However, it has not been investigated
in previous studies whether (a) PKC phosphorylates PARP
in the intact cell, (b) how this phosphorylation aﬀects the acti-
vation of the enzyme within an intact cell and (c) whether the
PKC-PARP interaction aﬀects the course of cell death. The
data shown in the current report conﬁrm in a cell-based system
that PARP-1 activity is inhibited by PKC activation. Further-
more, the current data with the PKC inhibitors suggest that –
at least in part – conventional (calcium-dependent) PKC iso-
forms mediate the response. In addition, the current results
demonstrate that the pattern of modulation of cell death re-
sponses by PKC activators and PKC inhibitors is consistent
with their eﬀects on PARP activation. In other words, inhibi-
tion of PARP activation by PMA mimics the eﬀect of the pro-
fessional PARP inhibitor compounds (see [10,15]) in
preventing necrotic type cell death, while shifting the cell death
pathways towards the apoptotic route (as evidenced by in-
creased caspase activation in cells challenged with MNNG
after pretreatment with PMA). Of note, when cell death or cell
injury is stimulated by oxidative stress (hydrogen peroxide)
rather than MNNG, a similar cytoprotective eﬀect of the
PKC activating phorbol esters could be observed. Moreover,
similar eﬀects have been obtained with PMA stimulation
in splenocytes representing a mature lymphoid population
(Fig. S2) but not in Jurkat T lymphoid cell line or adherent
cell lines (A549 lung epithelial cells, HaCaT keratinocytes)
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Fig. 2. PKC activation protects from MNNG-induced cytotoxicity. Cells were treated with 10 (A) or 20 (B) lM MNNG for 10 min. Some samples
were pretreated for 30 min with 100 nM PMA or with the PARP inhibitor PJ34 (3 lM). In some samples, PMA treatment was preceded with a
30 min treatment with the PKC inhibitors GF109203X and Go¨6976. Viability was determined in MTT reduction test (A) and necrotic death was
measured by propidium iodide uptake (B). Caspase activity, a measure of apoptotic death has been determined in a ﬂuorimetric assay (C). PKC
expression pattern of thymocytes has been determined by Western blotting (D). Data represent means ± S.D. of quadruplicate samples. Similar data
were obtained in three independent experiments. MNNG signiﬁcantly (**P < 0.01) reduced cell viability and increased necrotic cell death as
compared to control. PMA and PJ34 signiﬁcantly (##P < 0.01) inhibited the eﬀect of MNNG. The eﬀect of PMA was prevented by GF109203X
(P < 0.01) and by Go¨6976 (P < 0.01).
Fig. 3. PKC has no eﬀect on MNNG-induced DNA breakage. Cells were treated with 20 lMMNNG for 10 min. Some samples were pretreated for
30 min with 100 nM PMA or the PARP inhibitor PJ34 (3 lM) or glutathione (10 mM). In some samples, PMA treatment was preceded with a 30 min
treatment with the PKC inhibitors GF109203X and Go¨6976. Cells were embedded in low melting point agarose and DNA breakage was evaluated in
comet assay. Neither PJ34 nor PMA had any eﬀect on MNNG-induced DNA breakage. Representative images from three independent experiments
are shown.
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can be extended to more mature lymphoid cells but not to
transformed cell lines.
Indirect stimulation of the PKC signaling pathway, e.g. in
activated thymocytes or splenocytes may also lead to PARP
inhibition as indicated by our ﬁnding that stimulation of cellsfor 24 h but not for 1 or 6 h caused an inhibition ofMNNG-in-
duced PARP activation (Fig. S2). Moreover, immunoﬂuores-
cent staining for conventional PKC isoforms revealed that
PKC b1 but not other isoforms translocates into the nucleus
at 24 h following concanavalin A (conA) stimulation, whereas
it is localized to the cytoplasm at the earlier timepoints (Fig.
P 9
0’
P 5
0’
P 2
0’
P 0
’
C 9
0’
C 5
0’
C 2
0’
C 0
’
150
100
MW (kDa)
C
B IP: anti-PARP-1
WB: anti-PARP-1
PM
A 
PM
A+
GÖ
PM
A+
GF
R
el
at
iv
e 
de
ns
ityA
2.0
1.5
1.0
0.5
Co
ntr
ol
PM
A 
PM
A+
GÖ
PM
A+
GF
IP: anti-PARP-1
WB: anti-P-ser
Co
ntr
ol
**
2.5
#
##
Fig. 4. PKC phosphorylates PARP-1 in PMA-stimulated thymocytes.
Thymocytes were pretreated with the PKC inhibitors GF109203X and
Go¨6976 for 30 min followed by a 30 min exposure to PMA.
Phosphorylation of PARP1 was detected by two-way immunoprecip-
itation and Western blotting. Part A: PARP1 was immunoprecipitated
and phosphorylation was detected by P-Ser antibody. Part B. PARP1
was also detected for reference. Part C: Puriﬁed PARP1 was also
phosphorylated in vitro by PKC as detected by autoradiography. In
the control series (C0 0–C90 0) PKC was omitted from the reaction
mixture whereas complete reaction mixtures (P0 0–P900) contained
both PARP1 and PKC. Means ±S.E.M. or representative images from
at least three independent experiments are shown.
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inhibition of PARP-1 in activated thymocytes and splenocytes.
Our ﬁndings, demonstrating that in a cell-based system
PARP-1 is phosphorylated by PKC, and its activity is thereby
reduced, and this reduction can confer cytoprotection can be
viewed in the context of a multitude of published reports in
the area of PKC, PARP-1 and cell death. For instance, it
has been documented in multiple prior studies that cell death
induced by various stimuli including oxidants or pro-inﬂam-
matory cytokines has been shown to be suppressed by PKC
activating phorbol esters [18–22]. In addition, overexpression
of PKC suppresses cell death [23]. Furthermore, during hydro-
gen peroxide-induced oxidative stress, PKC becomes activated
and inhibits cell death in vascular smooth muscle cells [24] and
PKC inhibitors potentiate cell death in various systems [25–
27]. PKC has also been shown to mediate resistance to myo-
cardial infarction [28], a pathophysiological condition in which
myocardial necrosis is mediated in part by PARP activation
[29–31]. These lines of evidence point to an important role of
PKC in regulation of diﬀerent oxidant-induced cytotoxic pro-
cesses. Based on the results of the current studies, we hypoth-
esize that regulation of PARP-1 may be a pathway involved in
some of the previously reported cell-death-modifying eﬀects of
PKC modulators. In addition to regulating cell death, the reg-
ulation of PARP-1 activity by PKC may also contribute tosome of the signal transduction processes in the cell: Beckert
and colleagues have presented such an example in human
endothelial cells, where the IGF-1-induced VEGF expression
appears to be dependent on a PKC-mediated inhibition of cel-
lular PARP activity [32].
There are a number of observations in the current series of
experiments that indicate that alternative or parallel pathways
(other than the modulation of PARP by PKC) may also inﬂu-
ence cell death. For instance, one can notice that while PARP
phosphorylation induced by PMA was inhibited by both
Go¨6976 and by GF109203X (Fig. 4), the inhibition of PARP
activity by PMA was only partially reversed by Go¨6976, while
it was completely reversed in the case of GF109203X pretreat-
ment (Fig. 1). Nevertheless, both PKC inhibitors prevented the
protective eﬀect of PMA against MNNG-induced cell death in
the thymocytes to a comparable degree (Fig. 2). It is quite con-
ceivable that complex interactions of a multitude of PARP-
independent eﬀects and interactions are involved in the modu-
lation of cell death by PKC pathway modulators.
It may be interesting to note here that PKC has also been
shown to activate PARP-1 in ﬁbroblasts and human mono-
cytes [33,34]. Although several possible explanations (e.g. dif-
ferent cell types and conditions used in these studies) could
be given for this seeming contradiction with our current data,
we propose an alternative explanation. PMA may cause a low
level of PARP-1 activation leading to PARP-1 automodiﬁca-
tion which is known to inhibit the activity of the enzyme. In
PMA-pretreated cells, MNNG-induced massive DNA break-
age can thus only trigger a weak PARP activation which is
not suﬃcient to induce necrosis. Whether or not this may be
the case requires further investigation.
It appears that the evidence for PKC regulating PARP-1
activity and PARP-dependent cellular events is solid and multi-
ple. It is interesting to note that pathways that regulate towards
the reverse direction (PARP activity aﬀecting PKC activity) also
exist. A physical association between PARP and PKC and reg-
ulation of PKC signaling by PARP may be indicated by the
ﬁndings that PARP inhibition suppresses PKC activity [35,36].
In addition, PARP modulates the properties of MARCKS pro-
teins that are important substrates of PKC [36,37]. In endothe-
lial cells placed in elevated extracellular glucose, PKC activity is
regulated by PARP via the mitochondrial oxidant generation/
PARP activation/GAPDH inhibition connection [38].
In summary, the current study provides direct evidence for
the regulation of cellular PARP-1 activity by PKC in intact thy-
mocytes. In addition, the current study is the ﬁrst to implicate
the modulatory role of PKC activators and inhibitors in the
process ofMNNG-induced cell necrosis. Based on the data pre-
sented in the current report, we propose that PKC, (at least in
part) via modulation of endogenous cellular PARP-1 activity,
plays a signiﬁcant role in modulating cell death in thymocytes.
It will be interesting to study whether the modulation of PARP-
1 by PKC is also relevant for other cell types and whether it also
occurs in various disease conditions in vivo.Conﬂict of interest statement
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